Methylome Profiling and Biomarker Discovery Using MeDIP-Seq from Liquid Biopsy Samples

Xtalks
9/9/21, 2:00 PM
America/New York GMT -4 summer

Description

Epigenetic modifications, such as DNA methylation, have emerged as novel and promising key areas of cancer research in a liquid biopsy with broad potential applications in early cancer detection, risk assessment, prognosis, and prediction of response to therapy.

 

Cell-free methylated DNA (CfDNA) immunoprecipitation and high throughput sequencing (cfMeDIP-seq) is a highly sensitive, novel technique for non-invasive cancer detection and classification via identification of tumor-specific methylation patterns in cell-free DNA (cfDNA).

 

CfDNA methylation profiling provides several advantages over the methods based on somatic mutations. DNA methylation is a tissue-specific and stable epigenetic mark that allows one to determine the tissue of origin. In addition, each tumor type has a specific and defined methylome profile of hypermethylation of the CpG island in tumor-suppressor genes, which distinguishes cancer tissue from healthy tissue.

 

Register for this webinar to hear a discussion about the applications and analysis of cfMeDIP-seq in liquid biopsy with a special interest in cancer detection.

Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES

Methylome Profiling and Biomarker Discovery Using MeDIP-Seq from Liquid Biopsy Samples

Inglês

 

Speakers

Pier Vitale Nuzzo, Sandor Spisak